Over 90 Total Lots Up For Auction at One Location - WA 04/08

Amyvid now approved by European regulators

by Carol Ko, Staff Writer | January 16, 2013
Using Amyvid, doctors may be able to detect
plaques associated with Alzheimer's in PET scans
Eli Lilly and Company announced today that the Amyvid (Florbetapir (18F) solution, a radioactive agent used in PET brain scans that evaluate patients for Alzheimer's disease and other cognitive impairments, has been approved by the European Commission for diagnostic use.

One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaque, which degrades neurons in the brain and subsequently contributes to symptoms of Alzheimer's disease. Amyloid plaque may also indicate other serious cognitive impairments including neurological disorders, blood vessel-related disorders causing vascular dementia, movement disorders, brain tumors, normal pressure hydrocephalus and infections such as HIV.

Amyvid works by binding to amyloid plaque present in the brain, making the plaque visible in PET scans. A high presence of plaque indicates a stronger likelihood that the patient may have Alzheimer's Disease, though the scan on its own should not be used to independently establish a diagnosis.
stats
DOTmed text ad

New Fully Configured 80-slice CT in 2 weeks with Software Upgrades for Life

For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.

stats
Prior to this approval, the only way doctors could measure the presence of amyloid plaque was by autopsying the brain after death. In the future, using this new diagnostic tool may help physicians not only monitor and treat disease progression, but also diagnose disease more accurately. Studies show that up to one in five patients clinically diagnosed with Alzheimer's disease during life are ultimately misdiagnosed and do not exhibit Alzheimer's disease pathology upon autopsy.

Amyvid has already been approved for use in the United States by the FDA, and will be available in select areas within the European Union starting in the second quarter of 2013.

You Must Be Logged In To Post A Comment